natgillin/translations-raw huggingface dataset:
The signs of Parkinson’s disease get worse or getting similar signs – such as stiff muscles, difficulty in carrying out movements and muscle weakness
Pogoršanje znakova Parkinsonove bolesti ili pojava sličnih znakova – poput ukočenih mišića, otežanog izvođenja pokreta te slabost mišića
The signs of Parkinson’s disease get worse or getting similar signs – such as stiff muscles,difficulty in carrying out movements and muscle weakness
Pogoršanje znakova Parkinsonove bolesti ili pojava sličnih znakova – poput ukočenih mišića, otežanog izvođenja pokreta i mišićna slabost
The signs of Parkinson’s disease get worse – such as tremor, stiffness and shuffling
Pogoršanje znakova Parkinsonove bolesti – kao što su nevoljno drhtanje, ukočenost i poteškoće pri kretanju
The signs of urinary tract infection are:
Znakovi infekcije mokraćnog sustava su:
The signs or symptoms of bleeding and when to seek attention
znakovi i simptomi krvarenja i kada potražiti pomoć
The signs or symptoms of bleeding and when to seek attention from a healthcare provider
znakovima ili simptomima krvarenja i kada da potraže pomoć zdravstvenog djelatnika
The signs, symptoms and severity (including fatal outcome) will vary according to the location and degree or extent of the bleeding and/or anaemia (see section 4.9 Management of bleeding).
Znakovi, simptomi i težina (uključujući smrtni ishod) varirat će ovisno o mjestu i stupnju ili opsegu krvarenja i/ili anemije (vidjeti dio 4.9 „Zbrinjavanje krvarenja“).
The signs, symptoms, and severity (including fatal outcome) will vary according to the location and degree or extent of the bleeding and/or anaemia (see section 4.9 Management of bleeding).
Znakovi, simptomi i težina (uključujući smrtni ishod) varirat će ovisno o mjestu i stupnju ili opsegu krvarenja i/ili anemije (vidjeti dio 4.9 „Liječenje krvarenja“).
The signs, symptoms, and severity (including fatal outcome) will vary according to the location and degree or extent of the bleeding and/or anaemia (see section 4.9 Management of bleeding).
Znakovi, simptomi i težina (uključujući smrtni ishod) varirat će ovisno o mjestu i stupnju ili opsegu krvarenja i/ili anemije (vidjeti dio 4.9 „Zbrinjavanje krvarenja“).
The signs, symptoms, and severity (including fatal outcome) will vary according to the location and degree or extent of the bleeding and/or anaemia (see section 4.9 Management of bleeding).
Znakovi, simptomi i težina (uključujući smrtni ishod) varirat će ovisno o mjestu i stupnju ili opsegu krvarenja i/ili anemije (vidjeti dio 4.9. „Zbrinjavanje krvarenja“).
The sildenafil medium and high dose groups both showed PVRI reductions compared to placebo, of 18 % (95 %CI: 2 % to 32 %) and 27 % (95 %CI: 14 % to 39 %), respectively; whilst the low dose group showed no significant difference from placebo (difference of 2 %).
U skupini koja je primala srednju dozu sildenafila uočeno je smanjenje indeksa plućnog krvožilnog otpora u odnosu na placebo za 18% (95% CI: 2% do 32%), a u skupini koja je primala visoku dozu smanjenje za 27% (95% CI: 14% do 39%), dok u skupini koja je primala nisku dozu sildenafila nije zabilježena značajna razlika u odnosu na placebo (razlika od 2%).
The Sileo oral syringe is capable of delivering the product in 0.25 ml increments.
Štrcaljka za oralnu primjenu može primjenjivati proizvod u dozama od 0,25 ml.
The silica gel desiccant is contained in a separate sachet or canister and should not be swallowed.
Silika- gel kao sredstvo za sušenje nalazi se u posebnoj vrećici ili spremniku i ne smije se progutati.
The similar incidences of these events in both treatment arms, indicated that these adverse drug reactions are not attributable to VELCADE alone.
Slične incidencije ovih događaja u obje skupine, ukazale su na to da se ove nuspojave ne mogu pripisati samom VELCADEu.
The single and multiple dose pharmacokinetics of vedolizumab have been studied in healthy subjects and in patients with moderate to severely active ulcerative colitis or Crohn’s disease.
Farmakokinetika pojedinačne i uzastopnih doza vedolizumaba ispitana je na zdravim dobrovoljcima te u bolesnika s umjereno do izrazito aktivnim ulceroznim kolitisom ili Crohnovom bolešću.
The single dose pharmacokinetic parameters of NovoEight are listed in Table 4 for the clotting assay and in Table 5 for the chromogenic assay.
Farmakokinetički parametri jedne doze lijeka NovoEight navedeni su u Tablici 4 za test koagulacije i Tablici 5 za kromogeni test.
The single dose pharmacokinetics in healthy adults following oral administration of 2 Numient 195 mg levodopa/48.75 mg carbidopa capsules is presented in Figure 1.
Farmakokinetika pojedinačne doze u zdravih odraslih osoba nakon primjene kroz usta 2 kapsule Numienta od 195 mg levodope/48,75 mg karbidope prikazana je na Slici 1.
The single dose pharmacokinetics of zaleplon were studied in patients with mild (creatinine clearance 40 to 89 ml/min) and moderate (20 to 39 ml/min) renal impairment, and in patients on dialysis.
Farmakokinetika jednokratne doze zaleplona ispitana je u bolesnika s blagim (klirens kreatinina 40 do 89 ml/min) i umjerenim (20 do 39 ml/min) oštećenjem funkcije bubrega te u bolesnika na dijalizi.
The single injection will be
Jedna injekcija iznosit će
The single- dose pharmacokinetics of aripiprazole was linear and dose-proportional.
Farmakokinetika aripiprazola nakon primjene jedne doze bila je linearna i proporcionalna dozi.
The single-dose inter-subject variability in rivastigmine pharmacokinetic parameters (normalised to dose/kg bodyweight) was 43% (Cmax) and 49% (AUC0-24h) after transdermal administration versus 74% and 103%, respectively, after the oral form.
Varijabilnosti između pojedinih ispitanika s obzirom na farmakokinetičke parametre rivastigmina nakon jednokratne doze (prilagođeno prema dozi/kg tjelesne težine) bila je 43% (Cmax) i 49% (AUC0- 24h) nakon transdermalne primjene u usporedbi s 74% i 103% nakon oralne primjene.
The site of injection should be changed with each injection to avoid changes to the skin (such as thickening) that can make the insulin work less well than expected.
Mjesto injekcije treba promijeniti kod svake injekcije kako bi se izbjegle promjene na koži (poput zadebljanja) koje mogu smanjiti djelovanje inzulina u odnosu na očekivano.
The site of injection should be changed with each injection to avoid changes to the skin (such as thickening) that can make the medicine work less well than expected.
Mjesto injekcije treba promijeniti kod svake injekcije kako bi se izbjegle promjene na koži (poput zadebljanja) koje mogu smanjiti djelovanje lijeka u odnosu na očekivano.
The site of injection should be changed with each injection.
Mjesto injekcije treba se promijeniti pri svakoj injekciji.
The site of the procedure should be observed for signs of bleeding or haematoma formation.
Mjesto punkcije potrebno je kontrolirati zbog moguće pojave znakova krvarenja ili formiranja hematoma.
The site of the sodium chloride 9 mg/ml (0.9%) solution for injection bag where the needle is going to be inserted should be swabbed with an alcohol pad.
Mjesto na vrećici injekcijske otopine 0,9%-tnog natrijevog klorida (9 mg/ml) gdje će se umetnuti igla, treba prebrisati vatom natopljenom alkoholom.
The site of the sodium chloride 9 mg/ml (0.9%) solution for injection bag where the needle is going to be inserted should be swabbed with an alcohol pad.
Mjesto na vrećici otopine natrijevog klorida 9 mg/ml (0,9%) za injekciju gdje će se umetnuti igla treba prebrisati vatom natopljenom alkoholom.
The six-stage-decay of radium-223 to lead-207 occurs via short-lived daughters, and is accompanied by a number of alpha, beta and gamma emissions with different energies and emission probabilities.
Raspad radija-223 do olova-207 odvija se u šest stadija preko šest kćeri kratkog vijeka i praćen je brojnim alfa, beta i gama emisijama s različitim energijama i vjerojatnostima emisije.
The size of the capsule is ‘Size 1’ (dimensions 19.0 x 6.6 mm).
Veličina kapsule je 1 (dimenzije 19,0 x 6,6 mm).
The size of the capsule is ‘size 1’ (dimensions 19.4 x 6.9 mm).
Veličina kapsule jest „veličina 1” (dimenzije 19,4 x 6,9 mm).
The size of the capsule is ‘size 2’ (dimensions 18.0 x 6.4 mm).
Kapsula je „veličine 2“ (dimenzija 18,0 x 6,4 mm).
The size of the fibroids was also smaller in women treated with Esmya than in those who received the placebo.
Veličina fibroida također je bila manja u žena liječenih lijekom Esmya nego u slučaju žena koje su primale placebo.
The size of the sealant matrix depends on the size of the wound.
Veličina matrice tkivnog ljepila ovisi o veličini rane.
The size of the syringe (1 ml, 3 ml or 5 ml) will be included in your prescription.
Veličina štrcaljke (1 ml, 3 ml ili 5 ml) bit će navedena na receptu.
The skeletal effects of FORSTEO depend upon the pattern of systemic exposure.
Učinci lijeka FORSTEO na skelet ovise o obrascu sustavne izloženosti.
The skin discolouration generally disappears over a few days to weeks as the medicinal product is cleared.
Promjena boje kože obično nestaje za nekoliko dana ili tjedana nakon što se lijek ukloni iz organizma.
The skin effects of burning, stinging, tingling, rash and erythema were reported at higher levels in Vaniqa treated patients compared to vehicle, as indicated by the asterisk (*).
Učinci na kožu poput žarenja, peckanja, osipa i eritema prijavljeni su u većim razinama u bolesnica liječenih kremom Vaniqa u usporedbi s onima kojima je primijenjena podloga kako je naznačeno zvjezdicom (*).
The skin feels very hot with little or no sweating, or the child becomes confused or has muscle cramps, or the child’s heartbeat or breathing become rapid.
Koža je vrlo ugrijana uz malo znojenja ili bez znojenja, ili je dijete postalo smeteno ili ima grčeve u mišićima, ili su djetetovi srčani otkucaji ili disanje postali ubrzani.
The skin fold can be released after needle insertion.
Nakon umetanja igle možete otpustiti nabor kože.
The skin fold should not be released until the injection is complete.
Nabor kože se ne smije otpustiti prije nego je injiciranje dovršeno.
The skin fold should not be released until the injection is complete.
Nabor kože se ne smije otpustiti prije nego je ubrizgavanje dovršeno.
The skin surface area treated should be protected from solar exposure.
Površinu kože koja se liječi potrebno je zaštiti od izlaganja suncu.
the skin, check
kože, provjerite
The SLE Responder Index measures improvement in SLE disease activity, without worsening in any organ system, or in the patient’s overall condition.
Indeks odziva SLE-a mjeri poboljšanje vezano uz aktivnost bolesti, bez pogoršanja u bilo kojem organskom sustavu ili u općem stanju bolesnika.
The slow blinking green light means IONSYS is ready to dose.
Sporo trepereće zeleno svjetlo znači da je IONSYS spreman za isporuku doze.
The slowing in the progression to clinical proteinuria was evident as early as three months and continued over the 2 year period.
Smanjenje progresije klinič ke proteinurije bilo je vidljivo nakon tri mjeseca i nastavilo se tijekom 2 godine.
The slowing of peripheral joint damage was observed in patients with polyarticular symmetrical joint involvement.
Usporavanje oštećenja perifernih zglobova opaženo je kod bolesnika s poliartikularnim simetričnim zahvaćanjem zglobova
The small air bubbles will not harm you.
Mali mjehurići zraka neće Vam naškoditi.
The small amount of drug which was absorbed into the systemic circulation was promptly excreted by both urinary and faecal routes at a mean ratio of approximately 3 to 1.
Mala količina lijeka koja je apsorbirana u sistemsku cirkulaciju brzo je izlučena putem urina i fecesa pri srednjem omjeru od otprilike 3 naspram 1.
The small amount of F508del-CFTR that reaches the cell surface has low channel-open probability (defective channel gating).
Mala količina CFTR-a s mutacijom F508del koja dospije na površinu stanice ima malu vjerojatnost otvaranja kanala (nepravilna regulacija kanala).
the small green spoon measures 100 mg of betaine anhydrous powder;
mala zelena žličica mjeri 100 mg bezvodnog praška betaina;
The small increase in β agonist-related adverse events should be taken into account if doubling the dose of salmeterol/fluticasone propionate is considered by the physician in adult patients requiring additional short- term (up to 14 days) inhaled corticosteroid therapy.
Malo povećanje nuspojava povezanih s β-agonistom treba uzeti u obzir ako liječnik razmatra udvostručavanje doze salmeterola/flutikazonpropionata u odraslih bolesnika kojima je potrebna dodatna kratkotrajna (do 14 dana) terapija inhalacijskim kortikosteroidom.
The small rectangular window
Mali pravokutni prozorčić će nestati.
The SmPC for concomitantly used products must be consulted for the recommendations regarding co-administration with strong CYP3A4 inhibitors.
Treba pročitati sažetak opisa svojstava lijeka koji se istovremeno uzima radi preporuka o istovremenoj primjeni sa snažnim inhibitorima CYP3A4.
The SmPC of the actual SSRI/SNRI should be consulted on how to withdraw the treatment to avoid this.
Mora se postupiti prema sažetku opisa svojstava lijeka SSRI/SNRI u kojem je navedeno kako provesti prestanak liječenja da bi se to izbjeglo.
The SmPC section 4.4 includes a warning/precaution of use in children treated with high doses of Cystagon based on already reported cases of EDS on elbows, recommending to monitor regularly skin and to consider X-ray examination of the bone, and to decrease the dose of Cystagon if any similar or bone abnormality appear.
U dijelu 4.4 Sažetka opisa svojstava lijeka upozorava se na opreznu uporabu u djece liječene visokim dozama Cystagona na temelju već prijavljenih slučajeva EDS sindroma na laktovima i preporučuje redovito praćenje kože, razmatranje mogućnosti rendgenske pretrage kosti te smanjenje doze Cystagona ako se pojavi slična nuspojava ili abnormalnost kosti.
The sodium chloride 9 mg/ml (0.9%) solution for injection is added to the vial by slow, firm depression of the syringe plunger.
Injekcijska otopina 0,9%-tnog natrijevog klorida (9 mg/ml) dodaje se u bočicu sporim, čvrstim pritiskom klipa štrcaljke.
The sodium chloride 9 mg/ml (0.9%) solution for injection is added to the vial by slow, firm depression of the syringe plunger.
Otopina natrijeva klorida 9 mg/ml (0,9%) za injekciju se dodaje u bočicu sporim, čvrstim pritiskom klipa štrcaljke.
The solid pieces contain the medicine – do not chew or crush them.
Čvrste čestice sadrže lijek - nemojte ih žvakati niti drobiti.
The solubility of bosutinib is pH-dependent and absorption is reduced when gastric pH is increased (see section 4.5).
Topljivost bosutiniba je pH ovisna, a apsorpcija se smanjuje s povećanjem želučanog pH (vidjeti dio 4.5).
The solution (stabiliser) contains citric acid monohydrate (E330), lysine hydrochloride, polysorbate 80, sodium hydroxide and water for injections.
Otopina (stabilizator) sadrži citratnu kiselinu hidrat (E330), lizinklorid, polisorbat 80, natrijev hidroksid i vodu za injekcije.
The solution also contains potassium sorbate and sorbitol (E420).
Otopina također sadrži kalijev sorbat i sorbitol (E420).
The solution can be administered subcutaneously or intravenously.
Otopina se može primijeniti supkutano ili intravenski.
The solution can be diluted with 5 % glucose solution or sodium chloride 9 mg/ml (0.9%) solution for injection before intravenous injection.
Prije intravenske injekcije, otopina se može razrijediti 5%-tnom otopinom glukoze ili otopinom natrijeva klorida za injekciju od 9 mg/ml (0,9%).
The solution containing zoledronic acid is given as a single 15-minute intravenous infusion in a separate infusion line.
Otopina koja sadrži zoledronatnu kiselinu daje se kao jednokratna 15-minutna intravenska infuzija kroz zasebnu infuzijsku liniju.
The solution containing zoledronic acid is given as a single 15-minute intravenous infusion in a separate infusion line.
Otopina koja sadrži zoledronatnu kiselinu daje se kao jednokratna 15-minutna intravenska infuzija putem zasebne infuzijske linije.
The solution containing zoledronic acid is given as a single 15-minute intravenous infusion in a separate infusion line.
Otopina koja sadrži zoledronatnu kiselinu daje se kao jednokratna 15-minutna intravenska infuzija u zasebnoj infuzijskoj liniji.
The solution containing Zoledronic acid medac is given as a single 15-minute intravenous infusion.
Otopina koja sadrži Zoledronatnu kiselinu medac daje se kao jednokratna 15-minutna intravenska infuzija.
The solution containing zoledronic acid must not be further diluted or mixed with other infusion solutions.
Otopina koja sadrži zoledronatnu kiselinu ne smije se dodatno razdijeđivati niti miješati s drugim infuzijskim otopinama.
The solution contains 3 333 IU Epoetin zeta per ml.
Otopina sadrži 3333 IU epoetina zeta po ml.
The solution for infusion is an alternative form of treatment for a short period of time, when Vimpat can't be taken by mouth.
Otopina za infuziju alternativni je oblik za kratkotrajno liječenje, kada se Vimpat ne može uzeti kroz usta.
The solution for infusion is given to you by a health care professional, such as a doctor or nurse, via an intravenous infusion (a drip) approximately 30 minutes before you start your chemotherapy treatment.
Otopinu za infuziju dati će Vam liječnik ili medicinska sestra intravenskom infuzijom (dripom, tj. kap po kap) približno 30 minuta prije početka kemoterapije.
The solution for infusion is infused over a period of 15 to 60 minutes twice daily.
Otopina za infuziju se infundira u razdoblju od 15 do 60 minuta dvaput dnevno.
The solution for infusion is sterile, translucent and red.
Otopina za infuziju je sterilna, prozirna i crvena.
The solution for infusion may be stored for a maximum of 4 hours of the total 24 hours below 25°C. Do not freeze.
Otopina za infuziju može se čuvati najviše 4 sata od ukupno 24 sata na temperaturi ispod 25°C. Nemojte zamrzavati.
The solution for infusion may be stored for a maximum of 4 hours of the total 24 hours below 25°C. Infusion must be completed within 24 hours of reconstitution of the powder.
Otopina za infuziju može se čuvati najdulje 4 sata od ukupno 24 sata na temperaturi ispod 25°C. Infuzija se mora završiti u roku od 24 sata od pripreme praška za primjenu.
The solution for infusion must be administered via an infusion set with an in-line filter (pore size 0.2 μm to 1.2 μm) made of polyether sulfone (PES).
Otopina za infuziju mora se primijenjti pomoću kompleta za infuziju s ugraĎenim filtrom (veličina pora 0,2 μm do 1,2 μm) izraĎenim od polietersulfona (PES).
The solution for infusion must be administered via an infusion set with an in-line filter (pore size 0.2 μm to 1.2 μm) made of polyether sulfone (PES).
Otopina za infuziju mora se primjenjivati pomoću kompleta za infuziju s ugraĎenim filtrom (veličina pora 0,2 μm do 1,2 μm) izraĎenim od polietersulfona (PES).
The solution for infusion should be infused intravenously over 20 – 50-minutes.
Otopinu za infuziju treba dati kao intravensku infuziju tijekom 20 do 50 minuta.
The solution for injection can be stored between 2C to 30C for no more than 8 hours.
Otopina za injekciju može se čuvati na temperaturi od 2C do 30C najdulje 8 sati.
The solution for injection in a pre-filled pen is ready for use.
Otopina za injekciju u napunjenoj brizgalici spremna je za upotrebu.
The solution for injection in a pre-filled syringe is ready for use.
Otopina za injekciju u napunjenoj štrcaljki spremna je za upotrebu.
The solution for injection is only for use in rheumatoid arthritis and is given as an injection under the skin once a week.
Otopina za injekciju koristi se samo u slučaju reumatoidnog artritisa, te se primjenjuje injekcijom pod kožu jednom tjedno.
The solution for injection was compared with placebo over a period of two hours in two studies involving 805 adults with schizophrenia or related conditions who were experiencing symptoms of agitation.
Otopina za injekciju uspoređena je s placebom tijekom razdoblja od dva sata u dva ispitivanja koja su uključivala 805 odraslih osoba sa shizofrenijom ili srodnim stanjima koji su iskusili simptome agitacije.
The solution has a pH of approximately 6.0 and an osmolality of approximately 340 mOsm/kg.
Otopina ima pH od približno 6,0 i osmolarnost od približno 340 mOsm/kg.
The solution in the cartridge is stable for up to 28 days after first use when stored at 2 - 8°C.
Otopina u ulošku stabilna je do 28 dana nakon prve uporabe kad se čuva pri temperaturi od 2 – 8 °C.
the solution in the pre-filled syringe is clear to slightly opalescent (having a pearl-like shine) and colourless to light yellow
da je otopina u napunjenoj štrcaljki bistra do blago opalescentna (biserno sjajna) i bezbojna do svijetložuta
the solution in the pre-filled syringe is not discoloured or cloudy and does not contain any foreign particles the solution in the pre-filled syringe is not frozen.
da otopina u napunjenoj štrcaljki nije promijenila boju, nije zamućena ili ne sadrži strane čestice da otopina u napunjenoj štrcaljki nije smrznuta.
the solution in the vial is clear to slightly opalescent (having a pearl-like shine) and colourless to light yellow
da je otopina u bočici bistra do blago opalescentna (biserno sjajna) i bezbojna do svijetložuta
The solution in the vials should not be used if it is discoloured or if particulate matter is present.
Otopina u bočicama ne smije se koristiti ako je promijenila boju ili su u njoj prisutne čestice.
The solution is a colourless clear solution.
Bezbojna, bistra otopina.
The solution is a practically clear, orange solution for oral administration.
Otopina je gotovo bistra, narančasta otopina za peroralnu primjenu.
The solution is administered subcutaneously at a dose of 3 x 250 IU/kg b.w. per week.
Otopina se daje supkutano u dozi od 3 x 250 IU/kg tjel. mase tjedno.
the solution is any other colour than colourless to slightly yellow the pen has been dropped or is visibly damaged.
je otopina bilo koje druge boje osim bezbojne do blago žute je brizgalica pala ili je vidljivo oštećena.
the solution is clear and colourless and doesn’t contain particles the syringe has not been opened or damaged
da je otopina bistra i bezbojna i da nema stranih čestica da štrcaljka nije otvarana ili oštećena
the solution is clear and colourless to slightly yellow and doesn’t contain particles the syringe has not been opened or damaged
da je otopina bistra i bezbojna do žućkasta te da nema stranih čestica da štrcaljka nije otvarana ili oštećena
The solution is clear and pale yellow or light brown.
Otopina je prozirna i blijedožuta ili svijetlosmeđa.
The solution is clear and pale-yellow or light-brown.
Otopina je bistra, blijedo žute do svijetlo smeđe boje.
The solution is clear or slightly opalescent and colourless or pale yellow.
Otopina je bistra ili blago opalescentna, bezbojna ili blijedožuta.
The solution is clear or slightly opalescent and colourless or pale yellow.
Otopina je bistra ili slabo opalescentna i bezbojna ili blijedožuta.
The solution is clear or slightly opalescent and colourless to pale yellow.
Otopina je bistra ili blago opalescentna, bezbojna do blijedo žute boje.
The solution is clear or slightly opalescent and colourless to pale-yellow.
Otopina je bistra ili blago opalescentna i bezbojna do blijedo žute boje.
The solution is clear to opalescent and colourless to yellowish.
Otopina je prozirna do opalescentna te bezbojna do žućkasta.
The solution is clear, and colourless or pale yellow.
Otopina je bistra i bezbojna ili svijetložuta.
The solution is clear, colorless to pale yellow with a pH of 6.8 to 7.4.
Otopina je bistra, bezbojna do svjetložuta, pH vrijednosti 6,8 do 7,4.
The solution is clear, colourless to light yellow.
Otopina je bistra, bezbojna do svjetložuta.
The solution is cloudy or there are particles in it
Ako je otopina zamućena ili sadrži čestice.
the solution is cloudy or you can see particles floating in it
je otopina zamućena ili možete vidjeti da u njoj plutaju čestice
The solution is coloured or you can see particles floating in it.
Otopina je obojena ili sadrži vidljive plutajuće čestice.
The solution is coloured or you can see particles floating in it.
Otopina je obojena ili u njoj možete vidjeti plutajuće čestice.
The solution is colourless to slightly yellowish.
Otopina je bezbojna do blijedo žućkasta.